Download Biotie Therapies Corp. (Form: 6-K, Received: 06/30/2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE
ACT OF 1934
For the month of June, 2016
Commission File Number: 001-37423
Biotie Therapies Oyj
(Exact name of registrant as specified in its charter)
Biotie Therapies Corp.
(Translation of registrant’s name into English)
Joukahaisenkatu 6, FI-20520
Turku, Finland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F

Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes
No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes
No

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
BIOTIE THERAPIES CORP.
By:
Date: June 29, 2016
/s/ David Cook
Name:
David Cook
Title:
Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number
99.1
Description
Stock Exchange Release dated June 29, 2016 (9:15 a.m. EET): CHANGES IN THE MANAGEMENT TEAM
Exhibiy 99.1
BIOTIE THERAPIES CORP.
STOCK EXCHANGE RELEASE
29 June 2016, at 9.15 a.m. (EET)
CHANGES IN THE MANAGEMENT TEAM
Timo Veromaa, President and CEO of Biotie Therapies Corp. (“ Biotie ”, the “ Company ”) David Cook, CFO and Stephen Bandak, CMO of
Biotie are leaving the Company by June 30, 2016.
The Board of Directors of Biotie has appointed Antero Kallio, M.D., as the new CEO and Kristian Rantala as CFO for the Company, effective
July 1, 2016. Antero Kallio is currently the site head of Biotie’s operations in Turku, Finland and Kristian Rantala is vice president finance of
the Company. The responsibilities of the Chief Medical Officer will be divided among the Company’s research and development team staff
members as well as with Acorda Therapeutics’ interim Chief Medical Officer Burkard Blank, M.D.
Timo Veromaa was appointed President and CEO of Biotie in 2005. He has led the company through a number of pivotal transactions,
including financial restructurings, acquisition of Synosia Therapeutics Holding AG in 2011 and IPO of Biotie in the US in 2015.
“We thank Timo for his expertise, dedication and commitment to Biotie during more than a decade at the helm of the Company. Timo, David
and Stephen have been instrumental for the Company during the recent years, in particular in connection with the US listing and fundraise that
took place in 2015. We wish Timo, David and Stephen the best in their future endeavours” says Ron Cohen, Chairman of the Board of
Directors of Biotie.
Turku, 29 June 2016
THE BOARD OF DIRECTORS
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: [email protected]
DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media
INFORMATION REGARDING BIOTIE
Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has
delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled
out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in
Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.
For more information, please visit www.biotie.com.